31 Mar 2017 16:15
31 March 2017
Motif Bio plc
("Motif Bio" or the "Company")
Change of Registered Office
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces a change in its registered office. With immediate effect, its new registered office is: 27/28 Eastcastle Street, London W1W 8DH.
For further information please contact:
Motif Bio plc Graham Lumsden (Chief Executive Officer)
| info@motifbio.com
|
Zeus Capital Limited (NOMAD & BROKER) Phil Walker/Giles Balleny Dominic Wilson
| +44 (0)20 3829 5000 |
Northland Capital Partners Limited (BROKER) Patrick Claridge/David Hignell John Howes/Rob Rees (Broking)
| +44 (0)20 3861 6600 |
Walbrook PR Ltd. (FINANCIAL PR & IR) Paul McManus Mike Wort | +44 (0)20 7933 8780 or motifbio@walbrookpr.com Mob: +44 (0)7980 541 893 Mob: +44 (0)7900 608 002 |
MC Services AG (EUROPEAN IR) | |
Raimund Gabriel | +49 (0)89 210 2280 |
Notes to Editors:
Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials (Revive 1 and Revive 2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-1 is expected in the second quarter of 2017 and REVIVE-2 is on track for data readout in the second half of 2017.
MTFB.L (MTFB)